ClinicalTrials.gg
CompletedNCT00970281Updated Mar 7, 2012Results posted

A Study of Olanzapine in Patients With Schizophrenia

A Phase 3 interventional study of Rapid-Acting Intramuscular Olanzapine and Placebo in Schizophrenia, sponsored by Eli Lilly and Company. Completed at 11 sites in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2012-03-07.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
20 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.

Enrollment
57th of 94
91 · median 114
Started
2009
with 2 others
Phase 3
25 of 97
1 open now
Registered
62nd of 97
by date
Lead sponsor
22 of 97
Eli Lilly and Company

Among the 97 studies testing olanzapine in Schizophrenia, this one is the 57th largest by enrollment of the 94 interventional ones that give a count, is one of 3 that started in 2009, is one of 25 in phase 3, and was the 62nd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 20 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing olanzapine in Schizophrenia, or all of them as a file.
02

Study summary

The primary objectives of the study is to confirm if the efficacy of intramuscular injection (IM) olanzapine 10 milligrams (mg) in patients with an exacerbation of schizophrenia with acute psychotic agitation is greater than intramuscular placebo by comparing changes from baseline to 2 hours after the first IM injection of agitation.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who meet Fourth Edition Text Revision (DSM-IV-TR) criteria for schizophrenia.
  • Patients with an exacerbation of schizophrenia with acute psychotic agitation.
  • Patients who are hospitalized during the study.
  • Patients, or proxy consenters, understand the nature of the study and sign on an document.
  • The investigator or sub-investigator(s) judges that the patients are able to cooperate with all protocol procedures.
  • Patients who are considered to be with agitation and appropriate candidates for treatment with intramuscular (IM) medication by the investigator or sub-investigator(s).
  • The investigator or sub-investigator(s) believes that it is safe to administer IM olanzapine to the patients in consideration of safety, including the anticholinergic action of IM olanzapine.
  • Patients who have a score of 1 or 2 on Agitation-Calmness Evaluation Scale (ACES) before the first IM injection of product.

Exclusion criteria

Exclusion Criteria:

  • Patients whose Global Assessment of Functioning (GAF) score is less than or equal to 40 within last 1 year before .
  • Patients with defect.
  • Patients whose agitation continues more than 2 weeks before informed consent.
  • Patients who were previously treated with antipsychotics and were considered by the investigator or sub-investigator(s) to be treatment-resistant to antipsychotics.
  • Patients who were treated by oral olanzapine at a dose of more than 20 milligrams (mg) for more than 4 weeks but did not improve.
  • Patient who have a history of participation in clozapine trials or treatment with clozapine.
  • Patients who have co-morbidity of mental retardation and personality disorder.
  • Patients whose agitation is possibly due to brain lesions such as (but not limited to) head injury, stroke, brain breeding, and cerebral infection.
  • Patients with sub-stupor or stupor.
  • One or more seizures without a clear and resolved etiology. However, if the patient has had one or more seizures in the past with an identifiable etiology, and that etiology has been resolved, the patient may be entered.
  • Patients who have a history of substance (except caffeine and nicotine) abuse within the past 30 days or substance dependence within the past 6 months before informed consent. Or patients who have a history of using illegal drug.
  • Patients whose agitation is caused by substance abuse or neurologic conditions, in the opinion of the investigator or sub-investigator(s).
  • Patients who have a diagnosis of Parkinson's disease or dementia.
  • Patients who are actively suicidal (at high risk for suicide attempt) in the opinion of the investigator or sub-investigator(s).
  • Patients with inadequately controlled diabetes, or patients whose treatment for diabetes has been changed within 4 weeks before the first IM injection of the product. The investigator's discretion will supersede even if the patients do not meet the above criteria for concurrent diabetes.
  • Patients who have received haloperidol decanoate fluphenazine decanoate, or fluphenazine enanthate within 8 weeks before the first IM injection of investigational product.
  • Patients who have received risperidone long-acting injection within 12 weeks before the first IM injection of investigational product.
  • Patients who have a history of receiving injectable depot antipsychotics other than haloperidol decanoate, fluphenazine decanoate, fluphenazine enanthate and risperidone long-acting injection.
  • Patients who have received antipsychotics or other prohibited concomitant medicines within 2 hours before the first IM injection of investigational product.
  • Patients who have received benzodiazepines within 4 hours before the first IM injection of investigational product.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    10 mg Olanzapine

    Drug: Rapid-Acting Intramuscular Olanzapine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections

    Also known as: LY170053, RAIM

  • DrugPlacebo

    Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection

    Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.

    Time frame: Baseline, up to 2 hours after first IM injection

Secondary outcomes

  1. Change From Baseline in PANSS-EC Total Score up to 90 Minutes After the First Intramuscular (IM) Injection

    Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.

    Time frame: Baseline, 15 minutes, 30 minutes, 60 minutes, and 90 minutes after the first injection

  2. Change From Baseline in the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) Total Score up to 24 Hours After the First Intramuscular (IM) Injection

    Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.

    Time frame: Baseline, up to 24 hours after first IM injection

  3. Percentage of Participants With 40% or Greater Percent Decrease in the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection

    Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.

    Time frame: Up to 2 hours after the first (IM) injection

  4. Percentage of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) Score up to 24 Hours After the First Intramuscular (IM) Injection

    The ACES differentiates agitation, calmness, and sleep-state, using a 9-point scale: 1 (Marked Agitation) to 9 (Unarousable). Scores of 4 (Normal) to 7 (Marked Calmness) were used for this outcome measure.

    Time frame: up to 24 hours after the first IM injection

  5. Percentage of Participants With Treatment-Emergent Extrapyramidal Symptoms Based on the Drug Induced Extrapyramidal Symptoms Scale (DIEPSS) Score up to 24 Hours After the First Intramuscular (IM) Injection

    Assesses extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms; 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). Total points of 8 items are defined as DIEPSS total (0 to 32 points). Items for assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Parkinsonism is assessed by total points of items 1 to 5; akathisia, dystonia and dyskinesia are assessed by points given to corresponding items (item 6, item 7, and item 8, respectively).

    Time frame: Up to 24 hours after the first IM injection

07

Results

Posted Feb 22, 2012

Participant flow

Participant flow — Overall Study
Milestone10 mg OlanzapinePlacebo
Started4645
Full analysis set4545
Completed4429
Not completed216
Withdrew: Lack of efficacy114
Withdrew: Withdrawal by subject01
Withdrew: Physician decision11

Outcome measures

PrimaryChange From Baseline in the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection

Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.

Time frame:
Baseline, up to 2 hours after first IM injection
Reported as:
Mean · units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection
units on a scale10 mg OlanzapinePlacebo
Change From Baseline in the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection-9.2 ± 4.5-2.8 ± 5.6
Statistical analysis
  • 10 mg Olanzapine vs Placebo · ANOVA · p = <0.001 (The p-value was based on an analysis of variance (ANOVA) model that included treatment and site as a factor.)
SecondaryChange From Baseline in PANSS-EC Total Score up to 90 Minutes After the First Intramuscular (IM) Injection

Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.

Time frame:
Baseline, 15 minutes, 30 minutes, 60 minutes, and 90 minutes after the first injection
Reported as:
Mean · units on a scale
Change From Baseline in PANSS-EC Total Score up to 90 Minutes After the First Intramuscular (IM) Injection
units on a scale10 mg OlanzapinePlacebo
0.25 hour after First IM Injection-2.4 ± 2.9-1.0 ± 3.1
0.50 hour after First IM Injection-5.0 ± 3.6-1.9 ± 4.6
1 hour after First IM Injection-7.3 ± 4.9-3.0 ± 5.2
1.5 hour after First IM Injection-8.2 ± 4.7-2.7 ± 5.0
Statistical analysis
  • 10 mg Olanzapine vs Placebo · ANOVA · p = 0.009 (This is the p-value for 0.25 hour after first IM injection.)
  • 10 mg Olanzapine vs Placebo · ANOVA · p = <0.001 (This is the p-value for the 0.50 hour after first IM injection.)
  • 10 mg Olanzapine vs Placebo · ANOVA · p = <0.001 (This is the p-value for the 1 hour after first IM injection.)
  • 10 mg Olanzapine vs Placebo · ANOVA · p = <0.001 (This is the p-value for the 1.5 hour after first IM injection.)
SecondaryChange From Baseline in the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) Total Score up to 24 Hours After the First Intramuscular (IM) Injection

Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.

Time frame:
Baseline, up to 24 hours after first IM injection
Reported as:
Mean · units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) Total Score up to 24 Hours After the First Intramuscular (IM) Injection
units on a scale10 mg OlanzapinePlacebo
Change From Baseline in the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) Total Score up to 24 Hours After the First Intramuscular (IM) Injection-5.6 ± 5.8-2.8 ± 6.4
Statistical analysis
  • 10 mg Olanzapine vs Placebo · ANOVA · p = 0.008
SecondaryPercentage of Participants With 40% or Greater Percent Decrease in the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection

Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (absent) to 7 (extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.

Time frame:
Up to 2 hours after the first (IM) injection
Reported as:
Number · percentage of participants
Percentage of Participants With 40% or Greater Percent Decrease in the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection
percentage of participants10 mg OlanzapinePlacebo
Percentage of Participants With 40% or Greater Percent Decrease in the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection40.013.6
Statistical analysis
  • 10 mg Olanzapine vs Placebo · Fisher Exact · p = 0.008
SecondaryPercentage of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) Score up to 24 Hours After the First Intramuscular (IM) Injection

The ACES differentiates agitation, calmness, and sleep-state, using a 9-point scale: 1 (Marked Agitation) to 9 (Unarousable). Scores of 4 (Normal) to 7 (Marked Calmness) were used for this outcome measure.

Time frame:
up to 24 hours after the first IM injection
Reported as:
Number · percentage of participants
Percentage of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) Score up to 24 Hours After the First Intramuscular (IM) Injection
percentage of participants10 mg OlanzapinePlacebo
0.5 hour after First IM Injection24.411.4
1 hour after First IM Injection31.115.9
1.5 hours after First IM Injection40.013.6
2 hours after First IM Injection40.013.6
24 hours after First IM Injection28.915.9
Statistical analysis
  • 10 mg Olanzapine vs Placebo · Fisher Exact · p = 0.167 (This is the p-value for the 0.5 hour after the first IM injection.)
  • 10 mg Olanzapine vs Placebo · Fisher Exact · p = 0.134 (This is the p-value for the 1 hour after the first IM injection.)
  • 10 mg Olanzapine vs Placebo · Fisher Exact · p = 0.008 (This is the p-value for the 1.5 hour after the first IM injection.)
  • 10 mg Olanzapine vs Placebo · Fisher Exact · p = 0.008 (This is the p-value for the 2 hours after the first IM injection.)
  • 10 mg Olanzapine vs Placebo · Fisher Exact · p = 0.204 (This is the p-value for the 24 hours after the first IM injection.)
SecondaryPercentage of Participants With Treatment-Emergent Extrapyramidal Symptoms Based on the Drug Induced Extrapyramidal Symptoms Scale (DIEPSS) Score up to 24 Hours After the First Intramuscular (IM) Injection

Assesses extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms; 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). Total points of 8 items are defined as DIEPSS total (0 to 32 points). Items for assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Parkinsonism is assessed by total points of items 1 to 5; akathisia, dystonia and dyskinesia are assessed by points given to corresponding items (item 6, item 7, and item 8, respectively).

Time frame:
Up to 24 hours after the first IM injection
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Extrapyramidal Symptoms Based on the Drug Induced Extrapyramidal Symptoms Scale (DIEPSS) Score up to 24 Hours After the First Intramuscular (IM) Injection
percentage of participants10 mg OlanzapinePlacebo
Parkinsonism (N=43, 44)4.76.8
Akathisia (N=43, 45)0.00.0
Dystonia (N=44, 45)0.00.0
Dyskinesia (N=44, 45)0.00.0
Statistical analysis
  • 10 mg Olanzapine vs Placebo · Fisher Exact · p = 1.000 (This is the p-value for Parkinsonism.)

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10 mg Olanzapine—0/45 (0%)13/45 (28.9%)
Placebo—0/45 (0%)6/45 (13.3%)
Most frequent other events
Showing 10 of 20
Most frequent other events
Event10 mg OlanzapinePlacebo
SomnolenceNervous system disorders7/452/45
Blood urine presentInvestigations0/452/45
BradycardiaCardiac disorders0/451/45
ConstipationGastrointestinal disorders1/450/45
HaemorrhoidsGastrointestinal disorders1/450/45
Mouth haemorrhageGastrointestinal disorders0/451/45
NauseaGastrointestinal disorders1/450/45
FatigueGeneral disorders0/451/45
MalaiseGeneral disorders1/451/45
PyrexiaGeneral disorders1/451/45

Baseline characteristics

Age Continuous
Age Continuous(years)10 mg OlanzapinePlaceboTotal
Mean46.4 ± 11.747.0 ± 12.146.7 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)10 mg OlanzapinePlaceboTotal
Female212344
Male242246
Region of Enrollment
Region of Enrollment(participants)10 mg OlanzapinePlaceboTotal
Japan454590
Diabetes Mellitus Status
Diabetes Mellitus Status(participants)10 mg OlanzapinePlaceboTotal
Diabetes Mellitus - Yes336
Diabetes Mellitus - No424284
Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision Diagnosis Status
Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision Diagnosis Status(participants)10 mg OlanzapinePlaceboTotal
Catatonic022
Disorganized437
Paranoid404080
Undifferentiated101
Residual000
Pre-therapy Antipsychotic Usage
Pre-therapy Antipsychotic Usage(participants)10 mg OlanzapinePlaceboTotal
Yes (>=1000 milligrams [mg])121123
Yes (<1000 mg)273057
No6410
Age at Onset
Age at Onset(years)10 mg OlanzapinePlaceboTotal
Mean24.7 ± 9.427.2 ± 9.325.9 ± 9.4
Agitation-Calmness Evaluation Scale (ACES) Score
Agitation-Calmness Evaluation Scale (ACES) Score(units on a scale)10 mg OlanzapinePlaceboTotal
Mean1.6 ± 0.51.6 ± 0.51.6 ± 0.5

1 further baseline measures are reported on the registry.

08

Study locations

11 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aichi, 470-1168, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gunma, 3703603, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hokkaido, 0788208, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 234-0051, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kumamoto, 8660895, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nara, 634-8522, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okinawa, 9012111, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 593, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saitama, 343-0851, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 120-0005, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yamaguchi, 579-6613, Japan
09

References and documents

Publications

  • Katagiri H, Fujikoshi S, Suzuki T, Fujita K, Sugiyama N, Takahashi M, Gomez JC. A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation. BMC Psychiatry. 2013 Jan 11;13:20. doi: 10.1186/1471-244X-13-20. Erratum In: BMC Psychiatry. 2014;14:313. BMC Psychiatry. 2014 Dec 10;14:313. doi: 10.1186/s12888-014-0313-9. PubMed 23311957 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2009
First posted
Sep 2, 2009
Start
Sep 2009
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Results first posted
Feb 22, 2012
Last update
Mar 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00970281
Responsible party
Sponsor
First posted
Sep 2, 2009
Start date
Sep 2009
Primary completion
Apr 2011
Completion
Apr 2011
Results posted
Feb 22, 2012
Last update
Mar 7, 2012

Study contacts

Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM-5PM Eastern time(UTC/GMT-5hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion